Medical News

Act4Biosimilars: The Action Plan and Deep Dive Report for Europe are Now Live!

Act4Biosimilars is a global initiative that aims to increase patient access to biologics by facilitating greater Approvability, Accessibility, Acce...


Promising Approach in Treating Rectal Cancer: Rethinking Radiation Before Surgery

Radiation combined with chemotherapy, also known as chemoradiotherapy, is routinely given to people with rectal cancer whose tumours can be removed...


Understanding Metastatic Colorectal Cancer: A Call to Awareness on World Metastatic Colorectal Cancer Day

World Metastatic Colorectal Cancer (mCRC) Day stands as a symbol of hope and determination in the face of the challenges posed by this advanced sta...


Predictive Values of Blood-based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer

Presently, no widely recognised or established biomarkers are specifically designed to predict the effectiveness of FOLFIRINOX/FOLFOX (chemotherape...


DIPLOMA Trial: Minimally Invasive Surgery is an Effective Treatment Option for Early-Stage Pancreatic Cancer

A notable study, DIPLOMA, led by Abu Hilal, M.D., Ph.D., of the Istituto Ospedaliero Fondazione Poliambulanza in Brescia, Italy, involved a large c...


Personalized mRNA Pancreatic Cancer Vaccine Shows Promising Results in Small Trial

Messenger RNA (mRNA) vaccines – famous for preventing symptomatic infection of COVID-19—are starting to show some promise against pancreati...


ESMO Study Confirms Precision Oncology Remains Largely Inaccessible to European Cancer Patients

As a European umbrella organisation, DiCE is vocal in addressing the disparities associated with cancer patients’ access to precision medicin...


Primary and Updated Analyses for DESTINY-Gastric02 Study: Trastuzumab Deruxtecan Continues to Demonstrate Benefit in Metastatic Gastric and Gastro-oesophageal Cancer

Human Epidermal Growth receptor 2 (HER2) is a protein involved in normal cell growth, found in small amounts in almost all human cells, including s...


EU Commission Approval of Tibsovo® (Ivosidenib) in IDH1-mutated Cholangiocarcinoma

The European Commission approved the use of Tibsovo® (Ivosidenib) as monotherapy for the treatment of locally advanced or metastatic cholangiocarc...


Collaboration with COR2ED – HCC CONNECT

DiCE is pleased to collaborate with HCC CONNECT. HCC CONNECT is an international group of experts in hepatocellular carcinoma (HCC).



In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.